ArticleCancer cell international2024
Association between TAB2 genetic polymorphisms and the susceptibility to cervical cancer: a case-control study.
Article in Cancer cell international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundCervical cancer (CC) ranks as the fourth most common cancer and the fourth leading cause of cancer-related deaths among women globally, with declining incidence and mortality rates in recent decades. Previous studies have suggested that the transforming growth factor-beta (TGF-β) activated kinase 1 (TAK1) binding protein 2 (TAB2) can influence the stemness characteristics of squamous CC cells. However, the specific genetic impact of the TAB2 gene on CC remains unclear. This study aimed to evaluate the relationship between TAB2 genetic polymorphisms and susceptibility to CC using a hospital-based retrospective analysis.
methodsA total of 306 CC patients and 309 healthy controls were included in this study. Genetic analysis involved genotyping of subjects using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. Statistical analyses were conducted using SNPstats online analysis software and SPSS software.
resultsThe frequency of the G allele of rs521845 polymorphism was significantly higher in CC patients (P = 0.048, OR = 1.26, 95%CI = 1.00-1.59), with GG homozygotes showing an increased susceptibility to CC compared to CC/CG genotype carriers (P = 0.045, OR = 1.57, 95%CI = 1.01-2.45). Additionally, all three tag single nucleotide polymorphisms (SNPs) were associated with lymph node involvement in patients (P = 0.0006, OR = 0.01, 95%CI = 0.00-0.31 for rs237028 GG genotype; P = 0.009, OR = 0.17, 95%CI = 0.04-0.68 for rs521845 GG genotype; and P = 0.004, OR = 0.14, 95%CI = 0.03-0.59 for rs652921 CC genotype, respectively).
conclusionThis study highlighted that TAB2 rs521845 polymorphism was significantly associated with susceptibility to CC, suggesting that the TAB2 gene may play a crucial role in the progression of CC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.